Get the Stockscreener App
255.95
1.92%
-5.02
Penumbra Inc stock is traded at $255.95, with a volume of 376.47K.
It is down -1.92% in the last 24 hours and down -8.81% over the past month.
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products.
See More
Previous Close:
$260.97
Open:
$256.01
24h Volume:
376.47K
Relative Volume:
0.73
Market Cap:
$9.90B
Revenue:
$1.24B
Net Income/Loss:
$42.23M
P/E Ratio:
241.46
EPS:
1.06
Net Cash Flow:
$150.33M
1W Performance:
+0.09%
1M Performance:
-8.81%
6M Performance:
+3.39%
1Y Performance:
+36.64%
1-Day Range:
$249.09
$258.19
1-Week Range:
$249.09
$265.48
52-Week Range:
$148.00
$310.00
Penumbra Inc Stock (PEN) Company Profile
Name
Penumbra Inc
Sector
Industry
Phone
(510) 995-2486
Address
ONE PENUMBRA PLACE, ALAMEDA, CA
Compare PEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PEN
Penumbra Inc
|
255.95 | 9.90B | 1.24B | 42.23M | 150.33M | 1.06 |
|
ABT
Abbott Laboratories
|
132.28 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
SYK
Stryker Corp
|
373.37 | 147.15B | 23.22B | 2.86B | 3.58B | 7.40 |
|
BSX
Boston Scientific Corp
|
101.73 | 146.97B | 17.55B | 2.03B | 2.72B | 1.37 |
|
MDT
Medtronic Plc
|
86.17 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
73.27 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Penumbra Inc Stock (PEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-14-25 | Initiated | BofA Securities | Buy |
| Jan-21-25 | Initiated | UBS | Buy |
| Dec-17-24 | Initiated | Oppenheimer | Outperform |
| Dec-11-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-18-24 | Initiated | Stifel | Buy |
| Sep-03-24 | Initiated | Leerink Partners | Outperform |
| Jul-31-24 | Downgrade | Citigroup | Buy → Neutral |
| Jul-31-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-23-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-06-23 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Mar-29-23 | Downgrade | Needham | Buy → Hold |
| Jan-30-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Upgrade | Citigroup | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Oct-05-22 | Downgrade | Citigroup | Buy → Neutral |
| Sep-09-22 | Upgrade | Needham | Hold → Buy |
| Jul-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Apr-19-22 | Initiated | Deutsche Bank | Buy |
| Mar-08-22 | Initiated | Needham | Hold |
| Sep-16-21 | Initiated | Truist | Buy |
| Jun-04-21 | Upgrade | BTIG Research | Neutral → Buy |
| Dec-16-20 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-07-20 | Resumed | Canaccord Genuity | Buy |
| Sep-29-20 | Initiated | BTIG Research | Buy |
| Sep-08-20 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| May-30-19 | Upgrade | JP Morgan | Neutral → Overweight |
| May-21-19 | Initiated | William Blair | Outperform |
| Oct-29-18 | Resumed | BofA/Merrill | Buy |
| Oct-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Feb-21-18 | Initiated | William Blair | Outperform |
| Jan-02-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-30-15 | Reiterated | Canaccord Genuity | Buy |
| Oct-13-15 | Initiated | Wells Fargo | Outperform |
View All
Penumbra Inc Stock (PEN) Latest News
Inquis, Penumbra advance thrombectomy treatments - BioWorld MedTech
Transcript : Penumbra, Inc. Presents at 2025 Truist Securities MedTech Conference, Jun-17-2025 10 - marketscreener.com
Penumbra, Inc. Announces Completion of Enrollment for Landmark S - GuruFocus
Penumbra Completes Enrollment for STORM-PE Randomized Controlled Trial - Diagnostic and Interventional Cardiology
Penumbra completes enrollment in pulmonary embolism trial - MassDevice
Penumbra's Revolutionary PE Treatment Trial Hits 100-Patient Mark, Results Could Transform Blood Clot Care - Stock Titan
Clot Management Devices Market Set to Witness Significant - openPR.com
PEN Stock Rises Following the Launch of Ruby XL System - MSN
RSI Alert: Penumbra (PEN) Now Oversold - Nasdaq
Zacks Industry Outlook Penumbra, Integer and AngioDynamics - Yahoo Finance
Penumbra Introduces the Ruby XL System – the Longest, Largest, and Softest Coil on the Market for Vascular Embolization - HMP Global Learning Network
Insider Sell: Johanna Roberts Sells 600 Shares of Penumbra Inc (PEN) - GuruFocus
Penumbra Introduces the Ruby® XL Systemthe Longest, Largest, and Softest Coil on the Market for Vascular Embolization - StreetInsider
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Continues Penumbra (PEN) Fraud Investigation In Light Of Company’s Admissions, Encourages Investors to Contact its Attorneys Now - ACCESS Newswire
Penumbra Introduces the Ruby® Xl System - marketscreener.com
PEN Unveils Ruby XL System with FDA Clearance | PEN Stock News - GuruFocus
Penumbra Launches US FDA-Cleared Ruby XL Coil System - marketscreener.com
Penumbra announces FDA approval, launch of Ruby XL System - TipRanks
Just Launched: Penumbra's New Ruby XL System Delivers 40mm Coils Through Standard CathetersLargest in Market - Stock Titan
Penumbra’s EVP Johanna Roberts sells $154,903 in stock By Investing.com - Investing.com Canada
Penumbra’s EVP Johanna Roberts sells $154,903 in stock - Investing.com Australia
Transcript : Penumbra, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 09 - marketscreener.com
Transcript : Penumbra, Inc. Presents at 45th Annual William Blair Growth Stock Conference, Jun-03-2025 02 - marketscreener.com
Penumbra Inc (PEN) Shares Gap Down to $257.585 on Jun 2 - GuruFocus
Penumbra Insider Sold Shares Worth $4,366,920, According to a Recent SEC Filing - marketscreener.com
3 Reasons to Sell PEN and 1 Stock to Buy Instead - Yahoo Finance
Penumbra CEO Adam Elsesser sells $4.37 million in stock By Investing.com - Investing.com India
Penumbra CEO Adam Elsesser sells $4.37 million in stock - Investing.com Australia
Penumbra Amends Incorporation Certificate After Stockholder Vote - TipRanks
Managing Acute Limb Ischemia With Penumbra Lightning Bolt™ Technology - HMP Global Learning Network
Why Investors Shouldn't Be Surprised By Penumbra, Inc.'s (NYSE:PEN) P/S - simplywall.st
Why Is Penumbra (PEN) Down 10.6% Since Last Earnings Report? - Yahoo Finance
Penumbra (NYSE:PEN) shareholders are still up 88% over 3 years despite pulling back 3.1% in the past week - Yahoo Finance
Penumbra, Inc. to Present at Upcoming Investor Conferences - Eastern Progress
Penumbra Rallies 35.9% in a Year: What's Driving the Stock? - sharewise
Penumbra, Inc. to Present at Upcoming Investor Conferences | PEN Stock News - GuruFocus
Blend Extra: Stroke Awareness Month And How Quick Action Can Save Lives - TMJ4 News
Insider Sell Alert: Bridget O'Rourke Sells Shares of Penumbra Inc (PEN) - GuruFocus
Here's Why Penumbra (PEN) is a Strong Momentum Stock - Yahoo Finance
Penumbra EVP Johanna Roberts sells $268,697 in stock By Investing.com - Investing.com Nigeria
Penumbra EVP Johanna Roberts sells $268,697 in stock - Investing.com
Penumbra Inc Stock (PEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):